This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Roberto Francesco Bellini net worth and biography

Roberto Bellini Biography and Net Worth

Pres of BELLUS Health

Roberto Bellini has served as President and CEO of BELLUS Health since January 1, 2010.

Mr. Bellini previously oversaw the licensing and partnering activities of BELLUS Health Inc. His experience includes several roles and responsibilities at Picchio Pharma Inc., a joint venture healthcare investment firm owned by the Bellini Family Trust and Power Corporation of Canada, and its investee companies.

Mr. Bellini holds a Bachelor of Science in Biochemistry from McGill University.

How old is Roberto Francesco Bellini?: Mr. Bellini is currently 43 years old. There are 6 older executives and no younger executives at BELLUS Health. The oldest executive at BELLUS Health is Dr. Denis Garceau Ph.D., Chief Scientific Officer, who is 66 years old. Learn More on Roberto Francesco Bellini's age.
How do I contact Roberto Francesco Bellini?: The corporate mailing address for Mr. Bellini and other BELLUS Health executives is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. BELLUS Health can also be reached via phone at (450) 680-4500 and via email at [email protected]. Learn More on Roberto Francesco Bellini's contact information.
Has Roberto Francesco Bellini been buying or selling shares of BELLUS Health?: Roberto Francesco Bellini has not been actively trading shares of BELLUS Health during the past quarter. Learn More on Roberto Francesco Bellini's trading history.

Roberto Francesco Bellini Insider Trading History at BELLUS Health

Roberto Francesco Bellini Buying and Selling Activity at BELLUS Health

BELLUS Health Company Overview

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Today's Range

Now: $14.74

$14.74

$14.75

50 Day Range

MA: $14.62

$14.42

$14.75

2 Week Range

Now: $14.74

$6.38

$14.76

Volume

3,449,256 shs

Average Volume

3,081,445 shs

Market Capitalization

$1.87 billion

P/E Ratio

N/A

Dividend Yield